Anya Sharma - Peptides Today News and Research

The Unseen Risks: Understanding the Regulatory Void of Unapproved Peptide Injections

Anya Sharma December 13, 2025 No Comments

Unapproved peptide injections are becoming popular for fitness, anti aging, and weight loss. Many influencers promote these products as fast solutions for health goals. However, most of these injections do…

The Unseen Regulatory Battle: Peptides, Online Sales, and the Shifting Landscape of Doping Control

Anya Sharma December 8, 2025 No Comments

Online peptide doping is becoming one of the biggest silent problems in competitive sports today. The availability of unapproved peptides online has made it easier than ever for athletes and…

Navigating the Uncharted Waters: The FDA’s Stance on Unapproved Injectable Peptides

Anya Sharma November 20, 2025 No Comments

The growing interest in unapproved injectable peptides has created a new wave of wellness conversations. Many people believe these products offer quick benefits for anti-aging, performance, and recovery. However, most…

FDA’s “Green List” Import Alert: Securing the GLP-1 Peptide Supply Chain

Anya Sharma November 3, 2025 No Comments

The FDA green list for GLP-1 active pharmaceutical ingredients (APIs) marks a major shift in how the U.S. Food and Drug Administration monitors peptide imports. Announced in September 2025, this…

Increased Regulatory Oversight for “Research Use Only” Peptide Manufacturing

Anya Sharma November 3, 2025 No Comments

The landscape for peptide manufacturers, particularly those supplying products labeled “For Research Use Only” (RUO), is undergoing a significant transformation. Regulatory bodies are intensifying their scrutiny, shifting their enforcement focus…

Author: Anya Sharma

The Unseen Risks: Understanding the Regulatory Void of Unapproved Peptide Injections

The Unseen Regulatory Battle: Peptides, Online Sales, and the Shifting Landscape of Doping Control

Navigating the Uncharted Waters: The FDA’s Stance on Unapproved Injectable Peptides

FDA’s “Green List” Import Alert: Securing the GLP-1 Peptide Supply Chain

Increased Regulatory Oversight for “Research Use Only” Peptide Manufacturing

Sign up to Get Latest Updates